HMGB1-IN-1 (compound 6) exhibits potent inhibition of NO production in RAW264.7 cells, with an IC50 of 15.9 0.6 µM, and effectively disrupts the HMGB1/NF-kappaB/NLRP3 signaling pathway, demonstrating promising anti-inflammatory and anti-sepsis properties, particularly in the context of renal injury [1].
